SPRB
NASDAQSpruce Biosciences Inc.
Price$53.94+1.19 (+2.25%)
02:15 PM07:45 PM
News · 26 weeks55-75%
2025-12-282026-06-21
Mix2990d
- SEC Filings9(31%)
- Other7(24%)
- Insider5(17%)
- Offering3(10%)
- Leadership3(10%)
- Analyst2(7%)
Latest news
25 items- PRSpruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical AffairsDr. Jurecka Brings Deep Enzyme Replacement Therapy and Rare Disease Experience to Lead Medical Affairs and Scientific Engagement Ahead of Potential U.S. FDA Approval of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Agnieszka "AJ" Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs. "We are delighted to welcome AJ to the Spruce executive team. She is a rare combination of practic
- ANALYSTGuggenheim initiated coverage on Spruce Biosciences with a new price targetGuggenheim initiated coverage of Spruce Biosciences with a rating of Buy and set a new price target of $123.00
- PRSpruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate ControllerAppointments Further Strengthen Spruce's Commercial and Financial Capabilities as the Company Approaches a Potential U.S. FDA Approval and Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointments of Eric Jordan as Vice President, Marketing and Tina Gullotta, CPA, as Vice President, Finance and Corporate Controller."We are delighted to welcome both Eric and Tina, two accomplished leaders
- PRSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS SymposiumData Highlight TA-ERT's Potential as the First Disease-Modifying Treatment Option for MPS IIIB, a Fatal Condition With No Approved Therapies Treatment With Weekly TA-ERT Demonstrated Rapid and Durable Normalization of CSF Heparan Sulfate Non-Reducing End (CSF HS-NRE), a Surrogate Endpoint Reasonably Likely to Predict Clinical Benefit TA-ERT Stabilized and Preserved Cognitive and Non-Cognitive Outcomes, Including Communication and Motor Skills, Over a Six-Year Period Relative to Natural History Patients Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unme
- PRSpruce Biosciences Announces Data Presentation at the 18th International MPS SymposiumNicole Muschol, M.D. to Present Long-Term Data on Tralesinidase Alfa (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB) will be presented at the 18th International MPS & Related Lysosomal Diseases Symposium, taking place June 4-7, 2026 in Florence, Italy. International MPS Symposium Presentation Details Title: Lo
- PRSpruce Biosciences to Participate in Upcoming Conferences in JuneSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that members of the management team will present and participate in one-on-one meetings at upcoming conferences taking place in June. Jefferies Global Healthcare Conference Date and Time: June 4, 2026, at 11:05 a.m. ET Format: Presentation and 1x1 meetings Location: New York Interested parties can access the live webcast for the Jefferies Global Healthcare Conference on the events section of the Company's website. An archived copy of the webcast will be available for appr
- INSIDERSEC Form 4 filed by Director Spiegelman Daniel K4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- INSIDERSEC Form 4 filed by Director Simpson Camilla V4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- INSIDERSEC Form 4 filed by Director Barretto-Ko Percival4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- INSIDERSEC Form 4 filed by Executive Chairman Grey Michael G4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- INSIDERSEC Form 4 filed by Director Walbert Keli4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- SECSpruce Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Spruce Biosciences Inc.SCHEDULE 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Spruce Biosciences Inc.SCHEDULE 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Spruce Biosciences Inc.SCHEDULE 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECSEC Form S-8 filed by Spruce Biosciences Inc.S-8 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- SECSEC Form 10-Q filed by Spruce Biosciences Inc.10-Q - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- SECSpruce Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- PRSpruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesLong-Term TA-ERT Data Presented at the 22nd Annual WORLDSymposium™ Highlight Rapid and Durable Reduction of Heparan Sulfate and Stabilization of Cognitive Function in Patients with MPS IIIB Strengthened Leadership Team Across Commercial, Clinical Development, and Regulatory Functions to Support BLA Submission and Pre-Launch Readiness Closed Underwritten Public Offering for $69.0 Million in Gross Proceeds, Extending Cash Runway into the Second Half of 2027 and Beyond Anticipated Potential FDA Approval of TA-ERT Entered into Loan and Security Agreement with Avenue Capital for up to $50.0 Million in Term Loans to Strengthen Financial Flexibility Ahead of Potential U.S. Commercial Launch
- PRSpruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial OperationsSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointments of Brian Walls as Vice President, Market Access and Darren M. Johnson as Vice President, Commercial Operations. Mr. Walls brings more than 20 years of biopharmaceutical commercial leadership experience and has contributed to more than 18 product launches across rare, ultra-rare, oncology, neurology, and metabolic disorders. Most recently, he served as Vice President, Market Access at Applied Therapeutics, Inc. (acquired by Cycle Pharmaceuticals), where he arc
- SECSEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- ANALYSTCraig Hallum initiated coverage on Spruce Biosciences with a new price targetCraig Hallum initiated coverage of Spruce Biosciences with a rating of Buy and set a new price target of $140.00
- SECSpruce Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- SECSEC Form 424B5 filed by Spruce Biosciences Inc.424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- PRSpruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsSpruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the pricing of its previously announced underwritten public offering of 1,150,000 shares of its common stock at a price to the public of $50.00 per share and, in lieu of shares of common stock to a certain investor, pre-funded warrants to purchase 50,000 shares of common stock at a purchase price of $49.99 per share, which equals the public offering price per share of the common stock less the $0.01 exercise price per share of each pre-funded warrant. T
SPRB FAQ
7 questionsWhat does Spruce Biosciences Inc. do?
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH...Where does SPRB stock trade?
Spruce Biosciences Inc. (SPRB) is listed on NASDAQ.What sector and industry is SPRB in?
Spruce Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Spruce Biosciences Inc. go public?
Spruce Biosciences Inc. (SPRB) completed its IPO in 2020.What are analysts saying about SPRB?
Spruce Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy on 2026-06-16.What companies are similar to SPRB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SPRB side-by-side with any of them on Quantisnow.How can I track SPRB on Quantisnow?
Quantisnow aggregates Spruce Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SPRB to receive live email and push alerts on every new disclosure.